Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 31.
doi: 10.1111/vde.70009. Online ahead of print.

Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial

Sophie Forster  1 , Candace M Trout  2 , Simona Despa  2 , Annette Boegel  3 , Darren Berger  2 , Stephen King  2
Affiliations

Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial

Sophie Forster et al. Vet Dermatol. .

Abstract

Background: Inhibition of the Janus kinase pathway is an established treatment for allergic dermatitis.

Objective: To evaluate the efficacy and safety of ilunocitinib for control of pruritus in dogs with allergic dermatitis in a randomised, double-masked clinical trial.

Animals: Three-hundred-and-six dogs at 15 veterinary clinics.

Materials and methods: Enrolled client-owned dogs with severe pruritus and a presumptive diagnosis of allergic dermatitis were randomised to receive either ilunocitinib (n = 206; 0.6-0.8 mg/kg) or placebo (n = 100; 0 mg/kg) once daily for 28 days. Pruritus was assessed by owners using a pruritus Visual Analog Scale (PVAS). Treatment success was defined as ≥ 50% reduction from baseline PVAS on at least five of seven initial treatment days. Clinical remission from pruritus was considered achieved when PVAS < 2. Safety assessments were conducted over 112 days.

Results: On Day (D)7, 25.4% of ilunocitinib-treated dogs achieved treatment success compared to 7.7% of placebo dogs (p = 0.006). Starting on D3, the proportion of dogs with a ≥ 50% reduction from baseline PVAS was significantly higher in the ilunocitinib group (p < 0.01) and by D28, a significantly higher percentage of ilunocitinib-treated dogs (51.8%) achieved clinical remission compared to placebo dogs (12.7%; p < 0.05). Signs of dermatitis improved within 7 days. The 112-day ilunocitinib treatment was well-tolerated.

Conclusions and clinical relevance: Ilunocitinib administered once a day was well tolerated and effective at rapidly reducing pruritus, with steady and continuous improvement over time. Clinical remission of pruritus was achieved by 51.8% of ilunocitinib-treated dogs by D28, regardless of allergic aetiology.

Keywords: JAK inhibitor; allergic dermatitis; clinical remission; ilunocitinib; pruritus; skin lesions.

PubMed Disclaimer

References

    1. E. Bensignor, G. Marignac, O. Crosaz, and P. Cavana, “Pruritus in Dogs,” Veterinary Dermatology 24 (2013): 292.
    1. F. Sauvé, “Itch in Dogs and Cats,” Canadian Veterinary Journal 64 (2023): 686–690.
    1. C. Favrot, J. Steffan, W. Seewald, and F. Picco, “A Prospective Study on the Clinical Features of Chronic Canine Atopic Dermatitis and Its Diagnosis,” Veterinary Dermatology 21 (2010): 23–31.
    1. P. Hensel, D. Santoro, C. Favrot, P. Hill, and C. Griffin, “Canine Atopic Dermatitis: Detailed Guidelines for Diagnosis and Allergen Identification,” BMC Veterinary Research 11 (2015): 196.
    1. R. Marsella, “Advances in Our Understanding of Canine Atopic Dermatitis,” Veterinary Dermatology 32 (2021): 547.e151.

LinkOut - more resources